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OBJECTIVES We tested the hypothesis that salt and fluid retention in heart-transplant recipients (HTRs)
is caused by a failure to reflexively suppress the renin-angiotensin-aldosterone system
(RAAS).
BACKGROUND It is known that extracellular fluid volume is expanded (12% to 15%) in HTRs who develop
hypertension.
METHODS Responses to volume expansion were measured in eight HTRs (ages 57  6 years) and six
liver-transplant recipients (LTRs) (ages 52  2 years) both before and after treatment with
captopril (225 mg/day). After three days of a standardized diet, 0.154 mol/l saline was infused
at 8 ml/kg/h for 4 h. Blood pressure, hormones, and renal function were monitored for 48 h.
After four months, the same subjects received captopril (225 mg/day), and the protocol was
repeated.
RESULTS Before captopril, saline infusion suppressed the RAAS in LTRs but not in HTRs, resulting
in elimination of 86  12% versus 50  11% of the sodium load by 48-h postinfusion. Blood
pressure increased only in the HTRs (16  5/9  3 mm Hg) and remained elevated for
48 h (p  0.05). After captopril, sodium elimination was comparable in the liver (87  13%)
and heart groups (86  12%) and blood pressure did not change in either group.
CONCLUSIONS Heart transplant recipients have blunted diuretic and natriuretic responses to volume
expansion that is mediated by their inability to suppress the RAAS. Pharmacologic
suppression of the RAAS normalized defects in blood pressure and fluid homeostasis. These
findings indicate that hypertension in HTRs is caused, in part, by a failure to reflexively
suppress the RAAS when these patients become hypervolemic. (J Am Coll Cardiol 2003;
41:426–32) © 2003 by the American College of Cardiology Foundation
Hypertension is a frequent complication of heart transplan-
tation with as many as 80% of heart-transplant recipients
(HTRs) requiring treatment for this disorder (1–3). The
underlying pathogenic mechanisms remain unclear. Post-
transplant hypertension is unrelated to pre-existing hyper-
tension and refractory to standard antihypertensive pharma-
cologic therapy in some HTRs (1–3). Mechanisms
responsible for de novo hypertension in HTRs include
See page 433
vascular stiffness and endothelial dysfunction, which appear
to persist indefinitely after transplantation (3), and
cyclosporine-mediated side effects, including sympatho-
excitation (4) and nephrotoxicity (5). However, hyper-
tension in HTRs is more severe than in other transplant
populations and reductions in cyclosporine dose, serum
concentration, and duration of therapy fail to reduce the
incidence of hypertension (1–3). Moreover, HTRs who
never receive cyclosporine also have a high incidence of
hypertension (6). Against this background, it is appropriate
to conclude that de novo hypertension in HTRs extends
beyond cyclosporine-related mechanisms.
Our laboratory has focused upon the putative role of
extracellular fluid volume expansion in transplant hyperten-
sion. Extracellular fluid volume expansion (12%) is well
documented in HTRs who become hypertensive (7–10).
Theoretically, a fluid volume increase of only 3% to 4% can
result in sustained hypertension (11). In a previous study, we
acutely infused isotonic saline and determined that blood
pressure in HTRs is highly salt sensitive (8). We also
observed that HTRs have blunted diuretic and natriuretic
responses to fluid volume expansion that may be mediated
by a failure to reflexly suppress the renin-angiotensin-
aldosterone system (RAAS), secondary to cardiac denerva-
tion (8).
The purpose of this study was to determine whether salt
and water retention in HTRs are caused by an inability to
suppress the RAAS when these patients become hypervo-
lemic. We hypothesized that pharmacologic suppression of
the RAAS would normalize renal salt and water handling in
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HTRs. We further speculated that improved salt and water
elimination would lower systemic blood pressure. Using a
crossover design, we measured blood pressure, renal, and
endocrine responses to acute extracellular fluid volume
expansion in HTRs under standardized conditions both
before and after angiotensin-converting enzyme inhibition
(ACEi) with captopril (Capoten). Responses in HTRs
before and after ACEi were compared with responses in
liver-transplant recipients (LTRs), who served as both
cyclosporine and cardiac-innervated control subjects.
METHODS
Subjects. Eight male HTRs (57  6 years of age) were
entered into the study 22  4 months (group mean) after
transplantation. The HTRs were clinically stable and free
from significant rejection, infection, or other major illness
and all received immunosuppressive therapy with cyclospor-
ine, prednisone, and azathioprine. The HTRs were receiv-
ing maintenance prednisone of 5 to 10 mg/day at the time
of the study, and no HTRs required enhanced glucocorti-
coid doses within six months of the study. All HTRs had
biatrial anastomosis at transplantation. The HTRs under-
went endomyocardial biopsy within two months of the
study, and there was no evidence of rejection at the time of
biopsy in any of the subjects. Whole-blood cyclosporine
trough levels, calculated as an average of four determina-
tions over six months before the study were 225 18 ng/ml
(group mean). None of the transplant recipients were
hypertensive before transplantation, but all required antihy-
pertensive agents after transplantation. No HTRs had
evidence of cardiac allograft vascular disease. Six male LTRs
(52  2 years of age) immunosuppressed with cyclosporine
were also recruited to participate in the study as a cyclo-
sporine and cardiac-innervated control group. Whole-blood
cyclosporine trough levels, calculated as an average of four
determinations over six months before the study, were
similar in the heart (225  18 ng/ml) and liver (241  31
ng/ml) transplant recipients.
Study design. This study was a crossover design. Blood
pressure, renal, and endocrine responses to acute extracel-
lular fluid volume expansion were measured in the same
cohort of HTRs and LTRs under two conditions: study
period 1—after discontinuation of all diuretics and antihy-
pertensive agents; and study period 2, after a 14-day
regimen of ACEi consisting of a target dose of 225 mg/24
h of captopril. The two study periods were separated by 16
 5 weeks (mean SD). The protocol was approved by the
Institutional Review Board for the protection of human
subjects at the University of Florida and all subjects pro-
vided written informed consent to participate in the study.
Protocol without captopril. Diuretics and all antihyper-
tensive agents were discontinued 10 days before the study.
Antihypertensive agents included calcium channel blockers
(eight of eight HTRs), diuretics (four of eight HTRs), and
ACEi (two of eight HTRs). No alpha- or beta-blockers or
other cardiac medications were used by the transplant
recipients. Subjects were admitted to the clinical research
center (CRC). The first three days in the CRC consisted of
an equilibration to a diet that consisted of sufficient calories
to maintain current weight and provided 87 mEq/24 h of
Na and 80 mEq/24 h of K. Water intake was standard-
ized to 1,000 ml on day 3 but provided ad libitum on all
other days of the study. Consumption of alcohol, caffeine,
and tobacco products was not allowed.
Subjects were awakened each morning at 7:00 AM and,
while still supine, blood pressure was recorded in triplicate
using an automated system (Datascope Corp., Paramus,
New Jersey). Blood samples were drawn from an indwelling
venous catheter for analysis of plasma concentrations of
arginine vasopressin (AVP), angiotensin II (ANG II),
aldosterone (ALDO), and atrial natriuretic peptide (ANP).
A 24-h urine collection was started each morning at
7:00 AM. All subjects had 15% of Na balance before the
saline infusion studies conducted on day 4.
On day 4, the blood pressure, renal, and endocrine
responses to saline infusion were determined. At 7 AM the
subjects were awakened, blood samples were obtained, and
the subjects then stood and voided. Creatinine clearance was
determined from the 24-h urine sample. After 1 h, the
subject again voided and returned to the supine posture and
remained supine until completion of the infusion. Isotonic
saline (0.154 mol/l) was infused at 8 ml/kg/h for 4 h. Blood
pressure, heart rate, and blood samples were drawn before
the infusion and at 30, 60, 120, and 240 min during the
infusion. Urine was collected at 2 and 4 h during the
infusion. After completion of the infusion, an 8-h urine
collection was started. Thereafter, 12-h collections were
performed until the completion of the study. The 7-AM
sample collection regimen described earlier was repeated on
days 5 and 6. The protocol provided 48 h of observation for
blood pressure, renal salt and water elimination, and hor-
mone levels after onset of the volume expansion stimulus.
After the 48-h period of observation, the diuretic and
antihypertensive agents subjects received before study entry
were restarted, and the subjects were discharged from the
CRC.
Protocol with captopril. After approximately four months
(group mean 16  5 weeks), the same cohort of heart (n 
8) and LTRs (n  6) again discontinued all diuretic and
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ACEi  angiotensin-converting enzyme inhibition
ALDO  aldosterone
ANG II  angiotensin II
ANP  atrial natriuretic peptide
AVP  arginine vasopressin
CRC  clinical research center
HTRs  heart-transplant recipients
LTRs  liver-transplant recipients
RAAS  renin-angiotensin-aldosterone system
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antihypertensive agents. Subjects were then progressed
through a three-week home-based regimen of ACEi that
consisted of a target dose of 225 mg/day of captopril. After
14 days at the target ACEi dose, subjects were admitted a
second time to the CRC. The equilibration protocol and
volume expansion experiments described above were re-
peated for each subject. After a 48-h period of observation
and data collection, diuretic and antihypertensive agents
were restarted, and the subjects were discharged from the
CRC.
Blood sample collection. Blood samples for AVP, ANG
II, ALDO, and ANP were drawn into vacutainers contain-
ing ethylenediaminetetraacetic acid. Plasma was separated
by centrifugation at 3,500 g at 4°C for 20 min and the
samples were frozen at 80°C until the assays were per-
formed.
Neurohormone analyses. The plasma volume and neuro-
hormone assays used in the present study have been used
reliably in our laboratory for numerous experiments with
human subjects (8–10,12,13). Plasma AVP was measured
by radioimmunoassay as previously described (14). Plasma
ANG II and ALDO levels were determined by radioim-
munoassay as previously described by Braith et al. (12).
Atrial natriuretic peptide was extracted from plasma using a
modification of a technique described by Braith et al. (13).
Radioimmunoassay was performed with a kit from Penin-
sula Laboratories (Belmont, California) using ANP anti-
serum that has 0% cross-reactivity with human brain natri-
uretic peptide and C-type natriuretic peptide.
Electrolyte and creatinine analyses. Sodium and potas-
sium concentrations in urine and plasma were measured
using a Nova 1 electrolyte analyzer (Nova Biomedical,
Waltham, Massachusetts). Plasma osmolality was measured
with a vapor pressure osmometer (Westcor, Logan, Utah).
Standard methods were used for the measurement of serum
creatinine and the calculation of renal creatinine clearance.
Hemodynamics and left ventricular function. To evalu-
ate the possible contribution of cardiac function on fluid
volume status, HTRs underwent right heart catheterization
using standard thermodilution techniques and two-
dimensional echocardiography. These examinations were all
performed during the interval between the two CRC
admissions.
Statistical analysis. Hemodynamic, renal, and hormonal
responses in HTRs to the saline infusion before and after
ACEi and in liver transplant control subjects before and
after ACEi were compared using analysis of variance with
repeated measures and the Scheffe´ F test. Analysis of
variance was performed using the SAS general linear model
procedure (SAS Institute, Cary, North Carolina). An alpha
level of p  0.05 was required for statistical significance.
RESULTS
Clinical status. There were no changes in clinical status for
any HTR or LTR between the two admissions to the CRC.
There were no significant changes in body weight between
the protocol without captopril (94.3  6 kg) and the
protocol with captopril (93.1  7 kg). The immunosup-
pression regimen was not changed for any subject during the
study.
Cardiac function. The hemodynamic and left ventricular
function data in HTRs are presented in Table 1. The mean
cardiac index was 2.80  0.53 l/min/m2, which falls within
the lower one third of the normal range of 2.4 to 4.2
l/min/m2 (15). Right atrial pressure for the group was
slightly elevated at 6.1  1.0 mm Hg, which was 22%
greater than the accepted maximal right atrial mean pressure
of 5 mm Hg, whereas the mean occluded pulmonary artery
pressure of 10.3  3.2 mm Hg fell within the stated normal
range of 2 to 12 mm Hg (15). The results of our hemody-
namic measures are consistent with previous reports involv-
ing HTRs (16).
Blood pressure responses. Baseline systolic and diastolic
blood pressure values in HTRs with ACEi (131  8/84 
2 mm Hg) were significantly lower (p  0.05) than in
HTRs without ACEi (152  12/96  4 mm Hg). Baseline
systolic and diastolic blood pressure in HTRs with ACEi
was not significantly different (p  0.05) from pressure
values in LTRs either with (129  10/80  11 mm Hg) or
without ACEi (133 16/82 13 mm Hg). Baseline blood
pressure differences in LTRs before and after ACEi were
not significant (p  0.05). During the 4-h saline infusion,














1 7 18 3.73 8 10 60
2 6 10 3.43 10 11 55
3 10 14 2.48 9 10 60
4 8 8 2.39 11 11 46
5 6 4 3.40 8 9 60
6 6 13 1.90 10 10 58
7 6 8 1.96 9 9 55
8 4 7 3.10 9 10 60
Mean  SD 6.1  1.0 10.3  3.2 2.80  0.53 9.2  1.0 10.0  0.5 57.1  3.7
CI  cardiac index; EF  ejection fraction; HTRs  heart transplant recipients; IV Septum  ventricular septal thickness;
PCW  pulmonary capillary wedge pressure; PW  posterior ventricular wall thickness; RAP  right atrial pressure.
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systolic and diastolic pressure did not change (p  0.05) in
LTRs either before or after ACEi therapy (Fig. 1). In
contrast, HTRs without ACEi increased (p  0.05) both
systolic (16  5 mm Hg) and diastolic pressure (9  3
mm Hg) progressively throughout the infusion and re-
mained elevated (p  0.05) at 48-h postinfusion. Systolic
and diastolic pressure increased mildly during the 4-h saline
challenge in HTRs receiving ACEi, but the changes were
not statistically different (p  0.05) from baseline values.
Blood pressure in HTRs receiving ACEi was returned to
baseline values by 24 h after saline infusion.
Renal responses. Urine volume and urinary salt excretion
in HTRs during the 24 h preceding the plasma volume
measurements were not significantly different (p  0.05)
before (0.9  0.2 ml/kg/h; 3.6  0.2 mEq/h) compared
with after ACEi (0.8  0.3 ml/kg/h; 3.4  0.2 mEq/h).
Likewise, serum creatinine levels and 24 h creatinine clear-
ance in HTRs were not significantly different before (1.6 
0.4 mg/dl; 80.0  23 ml/min) compared with after ACEi
(1.5  0.5 mg/dl; 82.0  19 ml/min).
Urine volume during the 4-h saline infusion increased
similarly (p  0.05) in HTRs and LTRs both before and
after ACEi (Fig. 2). However, urine volume at 12 and 24 h
after the infusion was significantly (p  0.05) diminished in
HTRs without ACEi when compared with HTRs with
ACEi and LTRs both with and without ACEi. Urine
volume in liver patients after the saline infusion was not
different (p  0.05) before and after ACEi. The net urine
output over 48 h in LTRs was 82  15 ml/kg with ACEi
and 80  17 ml/kg without ACEi. The net urine output
over 48 h in HTRs was significantly greater (p  0.05) with
ACEi (78  11 ml/kg) than without ACEi (64  14
ml/kg).
Urinary salt elimination in LTRs during the 4-h saline
infusion was the same with and without ACEi (Fig. 2). In
HTRs before ACEi, however, natriuresis was significantly
less (p  0.05) during the 4-h saline infusion and remained
significantly diminished (p  0.05) until 36 h after the
saline infusion when compared with HTRs with ACEi and
LTRs with or without ACEi. A delayed natriuretic re-
Figure 1. Changes () in blood pressure during a 4-h infusion of isotonic
saline and the 48-h period after the infusion in heart- (HTR) and liver-
transplant recipients (LTR) both before (W/O ACEi) and after stabiliza-
tion (With ACEi) on captopril (225 mg/day). Data are mean value 
SEM. *p  0.05 versus baseline value. †p  0.05 HTRs before captopril
versus HTRs after captopril and LTR both before and after captopril.
ACEi  angiotensin-converting enzyme inhibition.
Figure 2. Changes in urine flow rate (UV) and urinary salt excretion
(UnaV) during a 4-h infusion of isotonic saline and the 48-h period after
the infusion in heart- (HTR) and liver-transplant recipients (LTR) both
before (W/O ACEi) and after stabilization (With ACEi) on captopril (225
mg/day). Data are mean value  SEM. *p  0.05 HTRs before captopril
versus HTRs after captopril and LTR both before and after captopril.
ACEi  angiotensin-converting enzyme inhibition.
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sponse (p  0.05) was observed in HTRs without ACEi
during the final 12-h collection period. Overall, HTRs
without ACEi excreted only 50  11% of the sodium load
by 48 h after the infusion. This was significantly less than
the corresponding values of 86 12% in HTRs with ACEi,
85  10% in LTRs without ACEi, and 87  13% in LTRs
with ACEi.
Endocrine responses. Baseline endocrine data are pre-
sented in Table 2. High-dose ACEi decreased (p  0.05)
supine resting ANG II levels (65% suppression) and ALDO
levels (75% suppression) similarly in HTRs and LTRs when
compared with those without ACEi. In LTRs without
ACEi, saline infusion caused reflex suppression of ANG II
and ALDO to values well below baseline (p  0.05) at all
measurement periods (Fig. 3). The ANG II and ALDO
levels returned slowly toward baseline over the next 48 h. In
stark contrast, saline infusion in HTRs both before and after
ACEi did not elicit reflex suppression of ANG II and
ALDO at any point during the 4-h infusion or 48-h
observation period. In LTRs receiving ACEi, saline infu-
sion suppressed ANG II and ALDO to levels that were
below the reliable detection limitation of our assay.
The changes in baseline supine resting AVP levels in
both HTRs and liver patients after ACEi did not reach
statistical significance (p  0.05), when compared with
values before ACEi (Table 2). In LTRs both before and
after ACEi, volume expansion elicited reflex suppression of
plasma AVP to levels that were significantly lower than
baseline values (Fig. 4). Conversely, in HTRs both before
and after ACEi, AVP values were not suppressed below
baseline during the infusion. Rather, there was a slight but
significant paradoxical rise in AVP during saline infusion
that is likely related to an inability to reflexly suppress AVP
and also to an increase in plasma osmolality.
Baseline ANP levels were elevated (p  0.05) in HTRs
compared with LTRs both before and after ACEi (Table 2).
The changes in baseline supine resting ANP levels in both
HTRs and LTRs after ACEi did not reach statistical
significance (p  0.05), when compared with values before
ACEi. Volume expansion elicited comparable increases in
ANP in both groups of subjects before and after ACEi (Fig.
4).
Cardiac responses. Volume expansion with isotonic saline
elicited a significant baroreflex-mediated decrease in supine
heart rate in the LTRs both before (63  5 to 58  4
beats/min) and after ACEi (62  4 to 57  3 beats/min).
However, heart rate remained constant throughout the 48-h
postinfusion observation period in HTRs both with (80 
7 to 80  9 beats/min) and without ACEi (79  7 to 80 
8 beats/min).
DISCUSSION
Principal findings. There were two main findings of this
study: 1) Short-term pharmacologic suppression of the
RAAS with high-dose captopril (225 mg/day) eliminated
avid salt and fluid retention in HTRs. Before ACEi, HTRs
demonstrated blunted and abnormally abbreviated diuresis
Figure 3. Changes () in plasma angiotensin II (ANG II) and aldosterone
(ALDO) concentrations during a 4-h infusion of isotonic saline and the
48-h period after the infusion in heart- (HTR W/O ACEi) and liver-
transplant recipients (LTR W/O ACEi) before stabilization on captopril
(225 mg/day). Data are mean value  SEM. *p  0.05 versus baseline
value. ACEi  angiotensin-converting enzyme inhibition.
Table 2. Baseline Fluid Regulatory Hormone Values in HTRs (n  8) and in liver Transplant









Angiotensin II (pg/ml) 5.6  1.2 1.9  0.8* 4.2  0.8 1.5  0.6*
Aldosterone (pg/ml) 168.0  22 41.8  10* 138.0  12 34.5  7*
Arginine vasopressin (pg/ml) 3.7  1.2 2.8  0.8 2.9  0.4 2.7  0.5
Atrial natriuretic peptide (pg/ml) 56.8  12† 47.5  10† 22.0  5 21.2  6
Values are mean  standard deviation. *p  0.05 before vs. after receiving captopril (ACEi). †p  0.05 HTR  LTR.
ACEi  225 mg/day captopril for 14 days; HTR  heart-transplant recipients; LTR  liver-transplant recipients.
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and natriuresis in response to acute fluid volume expansion
with isotonic saline. After ACEi, volume expansion elicited
brisk diuretic and natriuretic responses in HTRs. Before
ACEi, HTRs eliminated 50% of the salt load in 48 h. After
ACEi, HTRs eliminated 86% of the salt load in 48 h. 2)
HTRs are salt sensitive but defects in blood pressure
homeostasis during acute hypervolemia are normalized with
high-dose ACEi. Indeed, baseline systolic and diastolic
pressures in HTRs receiving ACEi were not significantly
different (p  0.05) from pressure values in normotensive
LTRs either with or without ACEi. Additionally, systolic
and diastolic pressure increased (p  0.05) during saline
infusion in HTRs before ACEi but not after high-dose
ACEi therapy. Our conclusions are strengthened by the
crossover study design with the same cohorts of HTRs and
LTRs studied before and after high-dose ACEi, with each
subject serving as his or her own control, as well as the
standardization of dietary salt, water, and caloric intake for
three days before the measurements.
Hemodynamic data and left ventricular function. Ab-
normal allograft systolic function is one possible alternative
explanation for salt and fluid retention in HTRs. Although
strong clinical evidence indicates occult diastolic dysfunc-
tion in HTRs (16), previously published data from our
laboratory (8–10) and the hemodynamic data for the sub-
jects of this study all indicate that cardiac index at rest is
maintained within the normal range, albeit generally toward
the lower one-third of the normal range. The echocardio-
graphic findings in the present study did not indicate
abnormal hypertrophy and confirmed normal left ventricular
systolic function (Table 1). Thus, with normal systolic
function, the avid salt and water retention that we observed
in HTRs before ACEi cannot be attributed to differences in
cardiac output. However, our hemodynamic and fluid ho-
meostasis measurements were not simultaneous. Rather, the
hemodynamic assessments in HTRs were performed during
the interval (16  5 weeks; group mean  SD) between the
first (without ACEi) and second (with ACEi) fluid balance
measurements, and therefore somewhat limit the generali-
zation of cardiac hemodynamic data to the physiologic state
of the patient at the specific times that fluid volume was
studied.
Cyclosporine and renal function. Most reports of fluid
retention in organ-transplant recipients have emphasized
cyclosporine-induced nephrotoxicity (1–6). The adverse
effects of cyclosporine include an increase in renal vascular
resistance and a concomitant decrease in the glomerular
filtration rate and renal blood flow; these effects are clearly
associated with fluid retention. In the present study, we
relied on the semiquantitative estimate of glomerular filtra-
tion rate using endogenous creatinine clearance. Although
this technique may not be sufficiently sensitive to detect
small differences in filtration in HTRs before and after
ACEi, our data indicate that the glomerular filtration rate
was the same in our cohort of HTRs before and after
high-dose ACEi. Our finding of normal salt and fluid
elimination in HTRs after ACEi, despite unchanged cyclo-
sporine dose and cyclosporine trough levels, clearly shows
that cyclosporine side effects alone are not an adequate
explanation for the avid salt and fluid retention observed in
HTRs. Moreover, defects in blood pressure and fluid
homeostasis were not observed in our control group of
LTRs despite the fact that they were receiving doses of
cyclosporine comparable to the HTRs. Rather, our findings
indicate that the moderate fluid retention that we have
described in HTRs is derived from the combination of a
deafferented heart (ablation of cardiac volume receptors and
failure to reflexively suppress the RAAS during hypervol-
emia) and the use of cyclosporine, which further attenuates
renal salt and water elimination.
Clinical relevance. Hypertension is a frequent complica-
tion of heart transplantation attributed to cyclosporine-
induced nephrotoxicity and endothelial dysfunction (1–4).
However, viewing the transplanted heart as a deafferented
volume-sensing organ provides an alternative explanation
for the incidence and severity of hypertension in HTR.
Extracellular fluid volume expansion (12% to 15%) is well
documented in clinically stable HTRs who become hyper-
tensive (7–10). Failure to reflexively suppress the RAAS
Figure 4. Changes () in plasma arginine vasopressin (AVP) and atrial
natriuretic peptide (ANP) concentrations during a 4-h infusion of isotonic
saline and the 48-h period after the infusion in heart- (HTR) and liver-
transplant recipients (LTR) both before (W/O ACEi) and after stabiliza-
tion (With ACEi) on captopril (225 mg/day). Data are mean value 
SEM. *p  0.05 versus baseline value. †p  0.05 HTRs versus LTR both
before and after captopril. ACEi  angiotensin-converting enzyme inhi-
bition.
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when HTRs become hypervolemic may be responsible, in
part, for the unique severity of de novo post-transplant
hypertension in some HTRs (10). In the present study,
infusion of 0.154 mol/l saline at 8 ml/kg/h for 4 h elicited
a hypertensive response (16  5/9  3 mm Hg), which
persisted for 48 h in HTRs without ACEi. Moreover, saline
infusion did not reflexively suppress AVP and the RAAS in
HTRs without ACEi. Net urine flow and urinary Na
excretion was blunted and delayed. In contrast, these defects in
blood pressure and fluid homeostasis were not observed in
LTRs receiving comparable doses of cyclosporine and they
were not observed in HTRs after pharmacologic suppression of
the RAAS with high-dose ACEi therapy.
Diuretic therapy may be ineffective at mitigating fluid
retention in HTRs. Initial decreases in plasma volume,
glomerular filtration rate, and renal blood flow return to
pretreatment values within 6 to 12 weeks of continuous
hydrochlorothiazide and furosemide therapy (17,18). Initial
doses of diuretic agents increase urine flow rate and renal
Na excretion and decrease body weight. However, with
repeated administration, progressive losses of salt and water
are soon curtailed. This diuretic braking phenomenon
appears to be independent of the class of diuretic agent
given and is achieved by a combination of renal Na
retention in the postdiuretic period and by resistance to the
natriuretic response to the diuretic agent (18).
This study was not designed to evaluate the effects of
long-term high-dose ACEi therapy. It is possible that
HTRs receiving prolonged high-dose ACEi therapy could
experience ACE escape, thereby rendering ACEi less effec-
tive at mitigating fluid retention. Morever, ALDO expres-
sion is known to continue in some patients with complete
inhibition of vascular-converting enzyme (19). ANG II
generation may occur via non-ACE pathways or ANG
II-independent stimulation of ALDO may occur through
intravascular depletion, increased plasma potassium concen-
trations, corticotropin, endothelin, and catecholamines (20).
Additionally, high-dose ACEi does not suppress AVP (Fig.
4). Therefore, AVP receptor antagonists may also be effi-
cacious in the long-term clinical management of fluid
retention in HTRs.
Study limitations. This study was limited by a small
sample size and the sequential order in which HTRs
participated in the two in-patient acute volume expansion
studies. However, despite the small sample and nonran-
domized order of experiments with and without ACEi, the
study is strengthened by the crossover design wherein each
subject served as their own control.
Conclusions. We demonstrated, in a small cohort of
HTRs, that although cyclosporine may contribute to hyper-
tension or fluid retention, the failure to reflexively suppress
the RAAS in response to acute volume expansion elicits the
full salt-sensitive hypertensive response. Abnormal cardio-
renal reflexes, secondary to cardiac denervation, appear to be
important modulators of blood pressure control and fluid
volume homeostasis in HTRs. Pharmacologic suppression
of the RAAS with high-dose ACEi (225 mg/day) elimi-
nated avid salt and fluid retention and the hypertensive
response to acute hypervolemia.
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